Department of Cardiac Surgery, Louis Pradel Cardiologic Hospital, Claude Bernard University, Lyon, France.
Research on Healthcare Performance RESHAPE, INSERM U1290, Université Claude Bernard Lyon 1, Lyon, France.
J Card Surg. 2022 Jun;37(6):1512-1519. doi: 10.1111/jocs.16456. Epub 2022 Mar 30.
Acute cardiovascular failure remains a leading cause of death in severe poisonings. Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used as a rescue therapeutic option for those cases refractory to optimal conventional treatment. We sought to evaluate the outcomes after VA-ECMO used for drug intoxications in a single-center experience.
We performed an observational analysis of our prospective institutional database. The primary endpoint was survival to hospital discharge.
Between January 2007 and December 2020, 32 patients (mean age: 45.4 ± 15.8 years; 62.5% female) received VA-ECMO for drug intoxication-induced refractory cardiogenic shock (n = 25) or cardiac arrest (n = 7). Seven (21.8%) patients developed lower limb ischemia during VA-ECMO support. Twenty-six (81.2%) patients were successfully weaned after a mean VA-ECMO support of 2.9 ± 1.3 days. One (3.1%) patient died after VA-ECMO weaning for multiorgan failure and survival to hospital discharge was 78.1% (n = 25). In-hospital survivors were discharged from hospital with a good neurological status. Survival to hospital discharge was not statistically different according to sex (male = 75.0% vs. female = 80.0%; p = .535), type of intoxication (single drug = 81.8% vs. multiple drugs = 76.1%; p = .544) and location of VA-ECMO implantation (within our center = 75% vs. peripheral hospital using our Mobile Unit of Mechanical Circulatory Support = 100%; p = .352). Survival to hospital discharge was significantly lower in patients receiving VA-ECMO during on-going cardiopulmonary resuscitation (42.8% vs. 88.0%; p = .026).
VA-ECMO appears to be a feasible therapeutic option with a satisfactory survival rate and acceptable complications rate in poisonings complicated by refractory cardiogenic shock or cardiac arrest.
急性心血管衰竭仍然是严重中毒患者死亡的主要原因。静脉-动脉体外膜肺氧合(VA-ECMO)已被越来越多地用作对最佳常规治疗无效的病例的抢救治疗选择。我们旨在评估在单中心经验中使用 VA-ECMO 治疗药物中毒的结果。
我们对我们的前瞻性机构数据库进行了观察性分析。主要终点是存活至出院。
2007 年 1 月至 2020 年 12 月,32 名患者(平均年龄:45.4±15.8 岁;62.5%为女性)因药物中毒引起的难治性心源性休克(n=25)或心脏骤停(n=7)接受 VA-ECMO 治疗。7 名(21.8%)患者在 VA-ECMO 支持期间出现下肢缺血。26 名(81.2%)患者在平均 2.9±1.3 天的 VA-ECMO 支持后成功撤机。1 名(3.1%)患者因多器官衰竭在 VA-ECMO 撤机后死亡,出院存活率为 78.1%(n=25)。住院幸存者出院时神经状态良好。根据性别(男性=75.0%比女性=80.0%;p=0.535)、中毒类型(单一药物=81.8%比多种药物=76.1%;p=0.544)和 VA-ECMO 植入部位(在我们中心=75%比我们的机械循环支持移动单元在周边医院使用=100%;p=0.352),出院存活率无统计学差异。在持续心肺复苏期间接受 VA-ECMO 治疗的患者出院存活率明显较低(42.8%比 88.0%;p=0.026)。
VA-ECMO 似乎是一种可行的治疗选择,在药物中毒并发难治性心源性休克或心脏骤停的患者中具有令人满意的生存率和可接受的并发症发生率。